文献速递妇科产科

改良衰弱指数预测妇科肿瘤减灭术联合HIPEC术后并发症

Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
PubMed 文献 · Gynecol Oncol · 2021-05-31

该单中心前瞻性注册研究纳入2014至2020年141例接受肿瘤细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)的晚期或复发妇科肿瘤患者,以改良衰弱指数(mFI)≥2定义衰弱。多因素分析显示mFI≥2与≥2级Accordion术后并发症显著增加相关(OR 9.4,95%CI 3.3–26.4,P<0.001)。

要点

  • mFI≥2的衰弱患者≥2级并发症风险显著升高(OR 9.4)。
  • 衰弱组再手术、ICU入住、急性肾损伤和呼吸衰竭发生率均更高。
  • CRS联合HIPEC术前应进行衰弱筛查以辅助患者选择。

核心结论

  • 改良衰弱指数(mFI)可预测妇科肿瘤患者CRS联合HIPEC术后≥2级并发症。
  • 术前衰弱筛查可能有助于患者选择和改善术后结局。

研究设计与样本

  • IRB批准的单中心前瞻性注册研究,查询2014年1月1日至2020年12月31日接受CRS联合HIPEC的晚期或复发妇科肿瘤女性。
  • 共纳入141例女性,衰弱定义为mFI≥2。
  • 采用Logistic回归评估mFI对≥2级Accordion术后并发症的影响。

主要发现

  • 141例中非衰弱(mFI 0–1)占81.6%(n=115),衰弱(mFI≥2)占18.4%(n=26)。
  • ≥2级并发症发生率:mFI=0为21.2%(n=14),mFI=1为26.5%(n=13),mFI=2为64.7%(n=11),mFI≥3为100.0%(n=9)。
  • 非衰弱 vs 衰弱:再手术1.7% vs 11.5%(p=0.044),ICU入住13.2% vs 34.6%(p=0.018),急性肾损伤6.3% vs 30.8%(p=0.001),呼吸衰竭0.9% vs 19.2%(p<0.001)。
  • 多因素分析中mFI≥2 vs mFI 0–1与≥2级并发症显著相关(OR 9.4,95%CI 3.3–26.4,p<0.001)。
  • 年龄(OR 1.04,95%CI 1.00–1.09,p=0.07)、手术指征复发vs原发(OR 0.71,95%CI 0.30–1.7,p=0.44)、手术复杂度评分中/高vs低(OR 1.5,95%CI 0.67–3.5,p=0.31)与≥2级并发症无显著关联。

关键数值与推荐

  • 衰弱定义:改良衰弱指数(mFI)评分≥2。
  • 并发症分级采用Accordion分级,终点为≥2级并发症。
  • mFI≥2 vs 0–1的≥2级并发症OR为9.4(95%CI 3.3–26.4,p<0.001)。

临床怎么用

  • 对拟行CRS联合HIPEC的妇科肿瘤患者,术前可用mFI≥2识别衰弱高危人群。
  • 衰弱患者术后需加强ICU、肾功能和呼吸功能监测。
  • 衰弱筛查可辅助患者选择和术前优化。

局限性

  • 单中心前瞻性注册研究,样本量141例,衰弱组仅26例。
  • 原文摘要未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To evaluate the impact of frailty on postoperative complications following cytoreductive surgery (CRS) with hyperthermic intra-peritoneal chemotherapy (HIPEC) in women with advanced or recurrent gynecologic cancer. METHODS: An IRB-approved single-institution prospective registry was queried for women who underwent CRS with HIPEC for advanced or recurrent gynecologic cancer from 1/1/2014-12/31/2020. Frailty was defined as a modified Frailty Index (mFI) score of ≥2. Logistic regression was used to assess the impact of mFI upon the rate of moderate or higher (≥ grade 2) Accordion postoperative complications. RESULTS: Of 141 women, 81.6% (n = 115) were non-frail with mFI of 0-1 and 18.4% (n = 26) were frail with mFI ≥2. The incidence of ≥ grade 2 complications was 21.2% (n = 14) for mFI = 0, 26.5% (n = 13) for mFI = 1, 64.7% (n = 11) for mFI = 2 and 100.0% (n = 9) for patients with mFI ≥3. The incidence of re-operation (1.7% vs. 11.5%, p = 0.044), ICU admission (13.2% vs. 34.6%, p = 0.018), acute kidney injury (6.3% vs. 30.8%, p = 0.001), and respiratory failure (0.9% vs. 19.2%, p < 0.001) were significantly lower amongst non-frail vs. frail women. On multivariable analysis, mFI ≥2 was associated with significantly increased ≥ grade 2 complications versus mFI of 0-1 (OR 9.4, 95% CI 3.3, 26.4, p < 0.001). Age (OR 1.04, 95% CI 1.00, 1.09, p = 0.07), surgical indication (recurrent vs. primary) (OR 0.71, 95% CI 0.30, 1.7, p = 0.44) and Surgical Complexity Score of Intermediate or High vs. Low (OR 1.5, 95% CI 0.67, 3.5, p = 0.31) were not associated with ≥grade 2 complications. CONCLUSIONS: Frailty, defined by the modified frailty index, is predictive of ≥grade 2 postoperative complications following CRS with HIPEC in women with gynecologic cancer. Frailty screening before CRS with HIPEC may assist patient selection and improve postoperative outcomes.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chambers LM, Chalif J, Yao M, et al. Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecol Oncol. 2021. PMID: 34083027. doi:10.1016/j.ygyno.2021.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。